How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder

Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes.  


OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interview today she walks me through how the company is preparing for their trials, how their approach differs to existing treatment options, and the impact on patient lives they hope to have. A leader in the UK biopharma industry, she also explains the strengths of the UK industry and how it can maintain an edge in the face of competition from Europe and the US.


01:07   Meet Ros Deegan


02:36   Cambridge and INSEAD


04:24   Building industry experience


05:16   Biotech in the US vs Biotech in the UK


06:19   OMass: mission and ambition


07:16   Funding the mission


08:18   The importance of partnerships


09:17   Industry and government


10:37   OMass and CAH


13:11   The differentiator for patient outcomes


14:49   Into the clinic in 2025


16:31   CAH patients and patient groups


19:29   The importance of hiring the right people


20:55   The Oxford ‘brand’ in biotechnology


22:17   Preparing for the clinic


23:43   Regulation and manufacturing


26:17   Partnering with top pharma


27:35   The importance of building value


28:41   How the UK can compete on a global scale


30:39   What’s next for OMass


32:59   The future of targeting rare disease


Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?u...)  


Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?...)


To dive deeper into the topic: 

• 10 biotech companies making a difference in rare diseases (https://www.labiotech.eu/best-biotech...)
• Rare Disease Day: seven drugs awaiting approval in 2025 (https://www.labiotech.eu/best-biotech...)